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1.1 Rationale of the Study: 
 
Equine influenza is one of the major diseases of the horse (Mumford, 1992; Lunn 
et al, 1999) and causes significant economic problems for the equine industry (Lai et al., 
2001). It is also one of the most common problems requiring veterinary attention (Traub-
Dargatz et al., 1991). It is an acute and contagious disease caused by two distinct 
subtypes: subtype 1 (H7N7) and subtype 2 (H3N8) of influenza A viruses, while subtype 
2 viruses are the major cause of respiratory disease in horses (Daly, Newton and 
Mumford, 2004).  
 
Equine influenza includes symptoms like fever, dyspnoea, anorexia, nasal 
discharge, coughing and weakness and it can lead to severe complications in horses 
(Chambers et al., 1995a, b; CDC Flu Home, 2005). Influenza A viruses are found in 
many animals, including ducks, chickens, pigs and horses, while Influenza B viruses are 
mainly found among humans (CDC, Flu Home, 2005).  
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Equine-1 influenza virus (H7N7) has not been recorded in circulation for more 
than twenty years (Webster, 1993). Though conventional vaccines are available for 
equine-2 influenza virus (H3N8), it is still common in circulation (Daly, Newton and 
Mumford, 2004).  
 
It has been found that current vaccines do not provide complete protection against 
equine influenza. Currently available vaccines are inactivated, live attenuated or vectored 
equine influenza vaccines (Daly, Newton and Mumford; 2004). It has been found that 
inactivated vaccines consisting of whole virus subtypes 1 and 2, or their subunits, do not 
provide complete protection for a longer period. The continuous emergence of new 
variants of viruses in the circulation and antigenic mismatching between viruses present 
in circulation and vaccines, are major reasons behind current vaccine failures (Palese and 
Garcia-Sastre, 2002; Daly, Newton and Mumford, 2004).  
 
Therefore, a safe and protective DNA vaccine is useful that can provide complete 
protection and can generate immunity for a longer duration. A DNA vaccine that can 
encode the hemagglutinin protein (HA) of equine influenza virus can have an important 
role in providing protection against equine influenza. This study aims to compare the 
effectiveness of DNA vaccines pTOPOKY98 and pVAXKY98 that encode HA1 from 
equine-2 virus, A/Eq/Ky/98 in eliciting protective immunity in mice. It also aims to 
compare the effectiveness of two vaccines using liposome and metastim as adjuvants. 
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1.2 Objectives of the study: 
 
a). Specific objective:  
 
The specific objective of the study was to evaluate the effectiveness of designed 
DNA vaccines pTOPOKY98#6 & pVAXKY98/11-9 in eliciting protective immunity in 
mice. 
 
b). General objectives:  
 
The general objectives of the study were as follows; 
• To compare the effectiveness of designed DNA vaccines pTOPOKY98#6 and 
pVAXKY98/11-9 expressing HA1 gene from equine-2 influenza virus. 
• To verify the expression of HA1 in Vero cells and Madin-Darby Canine Kidney 
(MDCK) cells. 
• To determine efficacy of intranasal DNA vaccination in mice.  
• To determine the level of protection by a weight loss model and by               
elevated IgG and IgA levels in mice serum after vaccinations. 
• To compare effectiveness of two vaccines using liposome & metastim. 
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1.3 Research Hypothesis: 
 
A DNA vaccine consists of a plasmid that encodes one or more genes of interest 
that can generate protective immunity against infection in a host. It is expected that after 
delivering designed DNA vaccines, HA1 protein will be produced in the antigen 
presenting cells and will be expressed in its native form in the host. The HA1, a segment 
of hemagglutinin protein, should be able to generate the protective immunity. This 
antigen presentation pathway is very much similar to that of a natural infection; therefore, 
a good immune response is expected towards this protein. 
 
Gurunathan et al. reported that when plasmid DNA is introduced into host cells, it 
is capable of the high level translation of its antigen and an immune response is elicited in 
response to antigen which is mediated by the cellular and humoral immunity of the 
immune system (Gurunathan et al., 2000). As reported by Abdelnoor, antigen presenting 
cells (APCs) play an important role in the induction of immunity by presenting vaccine 
peptides on MHC class I molecules and MHC class II molecules after antigen capture 
(Abdelnoor, 2001). 
Overall, humoral immunity along with mucosal immunity will be generated and 
an anamnestic response will also be generated after delivering a booster vaccination.  
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1.4 Methodology used in the study: 
 
In this study, two DNA vaccines pTOPOKY98#6 and pVAXKY98/11-9 were 
used for vaccination trial in mice. The cloning of vectors, design and characterization 
were done by Lai et al (unpublished data). The HA1 gene from equine-2 influenza virus, 
A/Eq/Kentucky/98, was cloned according to the manufacturer’s instruction (Invitrogen, 
CA) into these vectors and the both DNA preparations were amplified in Escherichia coli 
cells.  
 
For confirmation of correct DNA insert, the tissue transfection was performed 
using Vero cells and Madin-Darby canine kidney (MDCK) cells, in order to verify the 
expression of HA1 in cell cultures. For that, lipofection and electroporation methods were 
used to transfect cells with the DNA construct. Following the tissue transfection and 
incubation, cytosolic and nuclear fractions of cells were used and ELISA and PCR were 
performed for confirmation of HA expression in cells.  
 
A vaccination trial was designed using Balb/c mice to determine the effectiveness 
of the constructed DNA vaccines using a weight loss model and serum antibody levels. 
Mice were randomly selected and distributed into seven groups consisting of five mice in 
each group. Four groups of mice were vaccinated delivering designed DNA vaccines into 
the nasal cavity. A booster vaccination was given on day 21, after three weeks following 
the primary dose. A virus challenge was performed with homologous equine-2 influenza, 
A/Eq/KY/98 on day 42, after three weeks of booster vaccination.  
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The body weight of mice was recorded before and after vaccination and also after 
virus challenge. The HA specific IgG and IgA antibodies in serum were collected after 
the first vaccination and booster vaccination and also after virus challenge. A PROC 
GLM (ANOVA) method using SAS program (SAS Institute, 2004) was performed to 
determine significant differences in weight loss between the vaccinated and the 
unvaccinated groups and also to find out the significant differences in serum antibody 
levels before and after vaccinations.  
 
1.5 Significance of the study: 
 
DNA vaccination is a relatively new technology which has several advantages 
which include simple technology, genetic manipulation and chemical as well as 
biological stability (Whalen, 1996). Abdelnoor reported that plasmid DNA is 
thermostable and easy to freeze dry and at the same time it does not replicate in the host 
(Abdelnoor, 2001).  
 
DNA vaccines are found to be useful against infections, especially against viral 
diseases. After immunization, the antigens are produced in their native conformation for 
the generation of effective antibody responses. The protective immunity is generated by 
cellular and humoral responses (Donnelly, 1997; Abdelnoor, 2001). Therefore, DNA 
vaccines are not only safer than traditional vaccines, but also capable of providing 
increased protection (Johnson et al, 2000). Therefore, DNA vaccines will also be capable 





2.1 Equine Influenza virus:  
 
The equine influenza viruses are type A influenza viruses (Daly and Mumford, 
2001). There are two major subtypes of equine influenza virus, equine-1 influenza 
(H7N7) and equine-2 influenza (H3N8) viruses which are mainly found causing disease 
in horses (Lai et al., 2001; Daly, Newton and Mumford, 2004). Equine influenza virus is 
still a major infectious agent causing diseases in horses despite the regular administration 
of inactivated and live attenuated virus vaccines (Mumford et al., 1998; Daly, Newton 
and Mumford, 2004).  
 
2.1.1 Structure of Influenza virus: 
 
Influenza virus is a single stranded RNA virus. It is a pleomorphic virus, mostly 
found as spherical or ovoid structures. The size of virus ranges from 80-120 nm in 
diameter. The outer surface of lipid envelope consists of two types of glycoproteins, the 
hemagglutinin (HA), and neuraminidase (NA) (Flint et al., 2004). In the core, there is 
nucleoprotein which comprises eight segments of negative- stranded RNA. The matrix 
protein (M) is found in the inner side of the envelope.  
8
The 'RNP' is found in a helical shape associated with three polymerase polypeptides. PA, 
PB1 and PB2 are RNA-dependent polymerases present in virus while NS1 and NS2 are 
non-structural proteins associated with replication (Flint et al., 2004). 
 
2.1.2 Structure of hemagglutinin:
Hemagglutinin (HA) is the glycoprotein found on the virus surface (Flint et al., 
2004). The protein consists of two segments HA1 and HA2 joined by disulfide linkages 
and each monomer has a stalk that extends from the membrane and a globular head 
outside the membrane. This stalk is composed of an alpha-helix. The disulphide linkage 
between two segments dissociates during virus and host cell fusion (de Lima et al., 1995). 
The globular head consists of HA1 residues and the sialic acid binding pocket. There are 
four recognized antigenic sites: A, B, C, and D found around the receptor-binding pocket.  
 
2.1.3 Structure of neuraminidase: 
 
Neuraminidase (NA) is an important viral surface glycoprotein which plays a role 
in viral release after replication (Flint et al., 2004). It is responsible for removing sialic 
acid from newly synthesized HAs and NAs which are sialylated by cellular enzymes (Liu 
et al., 1995). In the absence of NA, virus release is inhibited and virions are found 
attached to the cell surface forming clumps on cell surface (Liu et al., 1995). von Itzstein 
et al. reported that NA could be considered a suitable target for antiviral drugs because it 
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possesses an active site whose amino acid sequence is conserved among all types and 
subtypes of influenza virus (von Itzstein et al., 1993). 
 
2.2. Classification of Influenza viruses: 
Influenza viruses are members of the Orthomyxoviridiae family and consist of 
two genera: influenza A and B viruses; and one additional influenza C virus. Influenza 
viruses are distinguished from one another on the basis of proteins M and RNP. Influenza 
A viruses are classified into subtypes based on the surface viral proteins: HA and NA. 
There are fifteen different HA and nine different NA subtypes of influenza viruses (Flint 
et al., 2004; CDC, Flu Home, 2005).  
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2.3 Immunological phenomena in influenza virus: 
 
2.3.1 Antigenic drift: 
 
Antigenic drift is the immunological phenomenon found in influenza virus due to 
spontaneous mutations in the surface proteins; HA and NA (Flint et al., 2004; CDC Flu 
Home, 2005). These mutations may cause slight changes in the amino acid sequence of 
the HA protein and will cause changes in antigenicity. Therefore, a drifted subtype of 
virus becomes selected in a population of partially immune hosts. Antigenic drift 
increases from year to year and is responsible for annual vaccine failures (Cann, 1993).  
 
2.3.2 Antigenic shift: 
 
Antigenic shift is another important immunological phenomenon seen in 
influenza virus that results from genetic reassortment of the RNA segments (Flint et al, 
2004; CDC, Flu Home, 2005). It takes place during replication, when two different 
viruses infect the same cell and when one virus takes HA genes from another virus. This 
phenomenon results in a major change in the antigenic structure of the virus (Gething et 
al., 1980) and generates mutant viruses of different subtypes. These new subtypes of 
virus emerge and can cause a pandemic. 
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2.3.3 Original antigenic sin: 
 
This is an immunological phenomenon seen in influenza virus where the host’s 
immune system fails to recognize new epitopes during subsequent infections caused by 
different strains of virus (Parham, 2005). This phenomenon is so named because original 
strain infection hampers the types of antibody made in response to future infections with 
different strains (Parham, 2005). In this process, the immune system uses only B cells 
which are rapidly mobilized. This allows virus a chance to escape from the protective 
immunity of a host; while the host’s immune system is prevented from responding to the 
changes in the virus. Therefore, a protective immunity to influenza is not acquired for a 




Influenza is an acute respiratory infection that has affected humans and animals 
since ancient times. Among equine viruses, two subtypes of equine influenza viruses 
were found in circulation, designated as the H7N7 and the H3N8 subtypes respectively 
(Oxburgh and Klingeborn, 1999). Webster reported that the first equine virus was 
isolated in Czechoslovakia in 1956 and this virus has not been recorded during the last 
two decades (Webster, 1993). Likewise, the first equine-2 influenza virus was isolated in 
1963 in Florida and found to be prevalent in most equine populations (Daly, Newton and 
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Mumford, 2004). It has been found in different parts of America, Europe and Africa 
except Australia and New Zealand (Oxburgh and Klingeborn, 1999).  
 
Oxburgh and Klingeborn reported that equine-2 influenza virus (H3N8) diverged 
into two lineages; European and American (Oxburgh and Klingeborn, 1999). Similarly, 
Lai et al reported that three American and one Eurasian lineages of the H3N8 virus have 
been identified (Lai et al., 2001). They were also reported in Europe and the United 
Kingdom. Lai et al. reported that only one strain of the virus belonging to the Eurasian 
lineage has been isolated in the Western Hemisphere (Lai et al., 2001).  
 
It has been found that equine-2 viruses are continuously emerging as new strains 
at regular time intervals (Lai et al., 2001; Daly and Mumford, 2001). The basis for this 
emergence is antigenic variation in HA and NA surface proteins i.e. antigenic drift and 
antigenic shift. As reported by Chambers, the outbreaks of equine influenza still occur 
irrespective of repeated vaccinations (Chambers, 1999). Furthermore, Daly, Newton and 
Mumford, reported that equine influenza epidemics caused by new strains of equine-2 
virus have been found in Europe, the American content and Asia since 1989 outbreaks in 
Europe, and therefore, there are antigenic variant strains of viruses in circulation (Daly, 
Newton and Mumford, 2004). The available inactivated and live attenuated vaccines are 
targeted to provide specific antibodies for currently circulating HA proteins (Daly and 
Mumford, 2001), while there is continuous emergence of new strains of equine-2 
influenza virus (H3N8) and this can be one of major reasons for vaccine failure.  
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There is an another phenomenon, known as the antigenic mismatching, which 
occurs between viruses that are currently circulating and viruses that are used as vaccine 
strains, is causing a great problem in the selection of strains for the development of 
vaccines (Palese and Garcia-Sastre, 2002; Daly, Newton and Mumford, 2004). The 
continuous emergence of new variants of viruses in the circulation is the reason behind 
antigenic mismatching. Therefore, the antigenic variation and evolution of new variants, 
and antigenic mismatching between viruses present in circulation and vaccines, are the 
major reasons behind current vaccine failures. 
 
2.4.1 Transmission of equine influenza: 
The equine influenza virus generally transmits through the air by droplets and 
particles excreted through coughing or sneezing (EquiFlunet, 2005). Aerosol 
transmission is the most important way of virus spread in horses. Disease spreads rapidly 
among the crowded population. Cold and dry weather promotes the viral survival outside 




It has been found that the unexposed and unvaccinated animals are found to show 
severe symptoms; while sub-clinical infection is also one of the significant ways for the 
spread of the virus (Daly, Newton and Mumford, 2004). It has been found that even 
vaccinated animals can infect others (Mumford, 1992).  
The transportation of horses is an important factor for transmission of disease 
over distances (Powell et al., 1995). Several factors like the contacts in close confinement 
(Powell et al., 1995), contaminated water, personnel and transport vehicles are found to 
be other major factors in disease transmission as reported by earlier studies (Guthrie, 
Stevens, and Bosman, 1999; Miller, 2000).  
 
2.4.2 Symptoms and complications of equine influenza: 
 
Equine influenza is an infection of the respiratory tract in horses and causes flu 
like symptoms (EquiFlunet, 2005). Generally, horses will show symptoms of disease 
within a period of one to five days and may recover in about two to three weeks. The 
disease is characterized by fever, chills, dry cough, nasal discharge, dyspnoea, and 
malaise (Wilson, 1993; Miller, 2000; EquiFlunet, 2005). Weakness and refusal of food 
and drink consumption are other symptoms during infection. Many horses may develop 




2.5 Immune system: role in influenza  
 
2.5.1 Innate immunity: 
Innate immunity is an important immunity in restricting harmful substances to 
enter the body that can cause disease. It is a non-specific immunity and works as the first 
line of defense. Some of important components of innate immunity against viruses are the 
skin, mucous, macrophage, complement, interferon and natural killer cell (Wise, Carter 
and Flores, 2005). It is also important for defense against infections caused by influenza 
virus (Tamura and Kurata, 2004). 
Interferons and natural killer cells are important for protection against viral 
infection (Wise, Carter and Flores, 2005). It was found that macrophages and natural 
killer cells in the lungs are capable of acting as antigen presenting cells and in destroying 
virus respectively (Price et al., 2000). Similarly, complement proteins are very important 
components of innate immunity, and play an important role in the neutralization of virus 
(Bernet et al., 2003). 
2.5.2 Acquired immunity: 
Acquired immunity is another important immunity which comes into play after 
antigen stimulation. In acquired immunity, there are two types of lymphocytes, B 
lymphocytes and T lymphocytes, which play an important role in generating immunity. It 
has been found that B lymphocytes are capable of producing antibodies while T 
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lymphocytes are capable of recognizing antigens associated with cells and destroying 
them (Wise, Carter and Flores, 2005).  
2.5.2.1 Cell mediated immunity: 
 Cell mediated immunity plays a very important role in influenza. Zinkernagel and 
Doherty reported that cytotoxic T lymphocytes (CTLs) lyse virus infected cells in a major 
histocompatibility complex-restricted manner (Zinkernagel and Doherty, 1979). 
Similarly, Braciale et al. reported that the HA protein of influenza A virus is a target 
antigen for CTLs (Braciale et al, 1984). Bennik et al. reported specific CTL responses in 
mice and humans to proteins like NP, PB1, PB2, and PA, M, and NS1 (Bennik et al., 
1982). Likewise, Townsend et al. showed that the NP of influenza A viruses are also 
important antigens for CTLs in mice and humans (Townsend et al., 1984). In addition, 
NS1 and the HA2 subunits of influenza A virus are also capable of inducing a protective 
CTL response in mice (Kuwano et al., 1990).  
2.5.2.2 Humoral immunity: 
 Humoral immunity is one of the very important forms of immunity for removing 
virus from the host. It, not only removes virus from the body, but also helps to generate 
specific memory responses. Antibodies are the main components of humoral immunity 
and it has been found that antigen presenting cells stimulate plasma cells to produce 
antibodies. Generally, IgM is produced in the primary response, while other isotypes such 
as IgG and IgA are produced later on maturation (Baumgarth et al., 1999).  IgA is a major 
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component of mucosal surfaces, while IgG is found in serum and in the lower respiratory 
tract (Gonchoroff et al., 1982) and considered to be major protective antibody. 
 
2.5.3 Mucosal immunity: 
 Mucosal immunity is vital in influenza because influenza viruses are respiratory 
pathogens. As reported by Ban et al., mucosal immunity is a major component of the 
immunologic response in the nasal passages (Ban et al., 1997). Similarly, Iwasaki and 
Kelsall reported that the mucosal microenvironment is usually found shifted toward the 
induction of T helper cells producing Th2 and Th3 cytokines (Iwasaki and Kelsall, 1999). 
It has been also shown that efficient B cell isotype switching to IgA depends on both T 
cells and the presence of cytokines such as IL-4, IL-5, IL-10 and TGF-β (Iwasaki and 
Kelsall, 1999). 
 In mucosal surfaces, specialized lymphoid tissues, known as the Mucosa-
associated lymphoid tissues (MALT) and Nasal associated lymphoid tissues (NALT), are 
found which play important roles in influenza. It has been found that T cells stimulate B 
cells to produce IgA and IgE (Davis, 2001). Several studies have shown that IgA has an 
important role in mucosal immunity (Kaetzel et al., 1991; Davis, 2001).  
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2.6 DNA vaccination: 
 
DNA vaccines are plasmid vectors that contain one or more genes of interest 
inserted under the control of a eukaryotic promoter that allows high level expression in 
mammalian cells (Abdelnoor, 2001). It is a relatively recent development in vaccine 
methodology.  
 
Considered as one of the major breakthrough works in DNA vaccination, Wolff et 
al found that the direct intramuscular inoculation of plasmid DNA encoding several 
different reporter genes could induce protein expression within muscle cells (Wolff et al, 
1990). Many other reports were published after the breakthrough study of Wolff et al. 
The findings of Tang et al. study (Tang et al., 1992) further supported the observation of 
Wolff et al.. Tang et al demonstrated that mice injected with plasmid DNA encoding 
hGH (human growth hormone) could elicit antigen-specific antibody responses (Tang et 
al, 1992). Likewise, Ulmer et al reported in Science that DNA vaccines could protect 
mice from influenza infection (Ulmer et al., 1993) and it is considered one of the major 
breakthroughs in DNA vaccine history. Similarly, Robinson et al reported that DNA 
vaccine could protect chickens from influenza (Robinson et al., 1993) and also 
contributed to DNA vaccine studies. 
 
There are several reports of investigations in many animals such as mice, ferrets, 
primates and chickens that reported the effectiveness of DNA vaccination against 
influenza infection (Montgomery et al.; Ulmer et al., 1993, Fynan et al., 1993, Iwasaki et 
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al., 1997, Wong et al., 2001; Epstein et al., 2002). However, there are not many reports in 
horses as compared to other animals. 
 
Fynan et al. reported that plasmid DNA expressing HA protein using different 
routes like parenteral, mucosal and gene gun inoculation methods could initiate protective 
immunity in mice (Fynan et al., 1993). They found 95% protection in mice using the gene 
gun method. They also found that the DNA quantity required was less in mucosal routes 
like trachea or nares and was successful in inducing protection. In the study of Wong et 
al, viral HA was delivered intranasally with liposome and was found to induce protection 
(Wong et al., 2001). In this study, both serum IgG and IgA were observed in response to 
vaccination.  
 
Similarly, Bot et al. reported that a plasmid bearing a HA gene from a virulent 
strain A/WSN/33 of influenza virus, was successful in generating protective immunity in 
newborn and adult mice (Bot et al., 1997). They found that a strongly biased Th1 
response was induced in adult mice whereas mixed Th1/Th2 responses occurred in 
neonates. They reported that a significant increase in survival was observed in these 
mice. Likewise, Johnson et al. reported that direct intramuscular injection of plasmid 
DNA induced Th1 responses and a high level of protection against live influenza virus 
challenge (Johnson et al., 2000). 
 
Some studies have been conducted in horses using DNA vaccines (Lunn et al., 
1999, Soboll et al., 2003). Lunn et al reported that delivery of HA encoding plasmid at 
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skin and mucosal sites in ponies was found to stimulate IgG responses and a poor IgA 
response (Lunn et al,. 1999). Similarly, Soboll et al reported that the DNA encoding HA 
and its co-administration with cholera toxin induced primary and mucosal IgA responses 
in ponies (Soboll et al., 2003). They also found local production of IgGb in nasal 
secretions and a significantly better virological protection in ponies was observed.  
 
2.6.1 Immunology of DNA vaccination 
 
It has been found that DNA vaccine induces both humoral and cellular responses 
(McDonnell and Askari, 1999; Abdelnoor, 2001). It is not very clear exactly how plasmid 
DNA is processed and presented to the immune system. Gurunathan et al. reported that 
there are at least three mechanisms by which the antigen is processed and presented to 
elicit an immune response. Those three mechanisms include direct priming by somatic 
cells like keratinocytes, myocytes, direct transfection of professional APCs like dendritic 
cells and cross-priming between somatic cells and APCs (Gurunathan et al., 2000).  
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2.6.2 MHC molecules and antigen processing pathways: 
 
MHC molecules are the gene products of the major histocompatability complex 
(MHC) gene locus (McDonell and Askari, 1999; Kumanovic et al., 2003).  These 
molecules play a major role in presenting processed antigens to T-lymphocytes 
(Abdelnoor, 2001). As reported by Abdelnoor, MHC class I molecules are expressed on 
the surface of practically all nucleated cells and consists of two polypeptide chains; an 
alpha chain and beta-2-microglobulin (Abdelnoor, 2001; Kumanovic et al., 2003). 
 
It has been found that only antigen presenting cells express MHC class II 
molecules and cytokine such as gamma-interferon may induce other cell types to express 
them (Abdelnoor, 2001). MHC class II molecules consist of two non-covalently linked 
polypeptides; the alpha and beta chains (Abdelnoor, 2001, Kuwanovic et al, 2003). 
 
Some of the examples of professional APCs which are important in antigen 
processing mechanism are dendritic cells, macrophages, Langerhans cells of the skin and 
B-lymphocytes (Abdelnoor, 2001). Abdelnoor also reported that APCs degrade protein 
antigens into smaller peptides and present the peptides to T-lymphocytes, and T-
lymphocytes are activated (Abdelnoor, 2001).  
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2.6.2.1 MHC class I presentation and cell mediated immunity: 
 
The MHC class I pathway, also known as the endogenous pathway, is important 
in stimulating cell-mediated immunity. McDonnell and Askari reported that DNA 
vaccines are capable of stimulating a cellular immune response in addition to the humoral 
response (McDonnell and Askari, 1999).  McDonnell and Askari also reported that DNA 
vaccines are able to generate cellular immunity because the foreign protein which they 
induce production, of is processed intracellularly and presented to the immune system in 
the context of the MHC class I system (McDonell and Askari, 1999). Traditional 
vaccines are processed via the MHC Class II system and therefore are not effective for 
cell-mediated immunity.  
 
Abdelnoor reported the mechanism for the MHC class I system processing and 
showed that the MHC class I system identifies and displays intracellular antigens. The 
intracellular proteins are cleaved into short peptides by proteosomes in the cytosol and 
these peptides bind to MHC class I molecules (Abdelnoor, 2001) at the lumen of the 
smooth endoplasmic reticulum with the help of TAP (transporters associated with antigen 
processing) molecules. The MHC-antigen complex reaches the cell surface through the 
Golgi apparatus and is expressed on the cell surface (Abdelnoor, 2001).  
 
Abdelnoor further reported that on the cell surface, the MHC-antigen complex is 
recognized by MHC class I restricted CD8+ cytotoxic T-cells. As a result, these CTLs are 
activated and amplified. In this manner, a cell-mediated immune response is generated 
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and CTLs are capable of identifying foreign proteins within all nucleated cells. In this 
way, cells infected with a virus may be detected and destroyed (Abdelnoor, 2001).  
2.6.2.2 MHC class II presentation and humoral immunity: 
 
The MHC Class II system which is also known as the exogenous pathway is the 
antibody pathway. This system processes exogenous antigens and presents them to 
stimulate helper T cells, which then stimulate B lymphocytes and antibody production 
(McDonell and Askari, 1999). MHC molecules are present on macrophages, neutrophils, 
some lymphocytes, dendritic cells and other antigen presenting cells (McDonell and 
Askari, 1999, Kuwanovic et al., 2003). But only specified antigen presenting cells 
express MHC class II molecules (Abdelnoor, 2001). These cells take up foreign antigen 
by phagocytosis or endocytosis (Kuwanovic et al, 2003). 
 
2.6.3 Dendritic cells in antigen presentation: 
 
Dendritic cells (DCs) are the most competent professional antigen presenting cells 
and important cells in antigen presentation to MHC molecules after DNA vaccination 
(Iwasaki and Kensall, 1999). The exact mechanisms responsible for the generation of 
MHC class I-restricted immune responses by DNA vaccination are still poorly 
understood (Corr et al., 1996), however, as reported by Gurunathan et al, a direct 
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transfection of professional APC or antigen transfer between transfected non-professional 
APC and professional APC are the most possible mechanisms for CTL induction upon 
DNA vaccination (Gurunathan et al, 2000).  
 
Gurunathan et al. reported that direct transfection of professional APC facilitates 
the use of the conventional Tap-dependent MHC class I presentation (Gurunathan et al, 
2000). As reported by Bot et al., among the professional APCs, the DCs play a critical 
role in the priming of MHC class I and II-restricted T cells (Bot et al., 2000). It is not 
clear to what extent DC that migrate from the area of DNA inoculation are responsible 
for the induction of MHC class I immunity but one possible explanation would be that 
the plasmid is picked up and expressed by the intraepithelial dendritic cells resident at the 
mucosal epithelium. 
 
2.6.4 Requirements of DNA vaccinations: 
 
The most important thing about a vaccine is that it should be able to provide 
protective immunity against infection. Some of the important requirements of DNA 
vaccine are cloning sites, enhancer promoters, selectable markers, polyadenylation 
sequences and a bacterial origin of replication (Gurunathan et al., 2000). The plasmid 
DNA vaccine should contain cloning sites where the gene of interest can be inserted. 
Likewise, it should contain selectable markers like antibiotic resistance genes to enable 
selection and also contain a bacterial origin of replication which is required for 
replication in bacteria. As reported by Robinson et al., a viral promoter for enhanced 
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expression in mammalian cells is useful (Robinson et al, 1993) and for that purpose, viral 
promoters from cytomegalovirus and SV40 virus are normally used. Polyadenylation 
sequences derived from SV40 virus or from bovine growth hormones are incorporated to 
stabilize mRNA transcripts (Gurunathan et al., 2000). 
 
2.6.5 Routes of DNA vaccinations: 
 
The reported common routes for DNA vaccinations are intra-muscular, 
subcutaneous, intra-peritoneal, intra-dermal, subcutaneous, intravenous, oral, rectal, intra-
tracheal, vaginal and intra-nasal routes (Simmonds et al, 1997; Abdelnoor, 2001). Out of 
these routes, the most common routes of administration in use are intra-muscular or intra-
dermal using a hypodermic needle or using a gene gun.  
 
Intranasal routes have been found to be useful in inducing mucosal immunity. 
Glueck reported that intranasal delivery of DNA influenza vaccines has been found to be 
able to induce protective mucosal immunity (Glueck, 2001). The intranasal 
administration of DNA vaccines is easier in comparison to other methods. The nasal 
mucosa is easily accessible and highly vascular, and has a large surface for absorption. 
Davis reported that this route was capable of eliciting both systemic and mucosal 
responses and distant mucosal cells can also be involved in the response due to 
dissemination of effector cells (Davis, 2001). 
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2.6.6 Delivery vehicles of DNA vaccines: 
 
Liposomes are the most commonly used vehicle for vaccines (Mannino and 
Gould-Fogerite, 1988; Gao and Huang, 1995). It has also been found that after being 
phagocytosed by antigen presenting cells or macrophages, liposomal antigen readily 
escapes from endosomes into the cytoplasm. It has also been found that liposomal peptide 
antigen can enter either the Golgi apparatus or the endoplasmic reticulum and thereby 
interact with MHC class II or class I molecules. (Audibert and Lise, 1993).  
MetaStim has been commonly used in equine vaccines for many years by Forte 
Dodge Animal Health (FDAH, 2005). According to the Forte Dodge Animal Health 
(FDAH, 2005): “MetaStim has proven itself over the years to provide excellent 
stimulation of the immune system and does not stimulate local inflammation”. This 
adjuvant system has been found to increase both short term and long term immune 
responses (Divers et al., 2000). 
 
2.6.7 Advantages of DNA vaccinations: 
 
As reported by Bot et al., plasmid DNA induces both cell mediated and humoral 
immunity (Bot et al, 1997). It is found to be non-infectious and does not replicate in the 
host (Abdelnoor, 2001). It is thermostable, easy to freeze dry and reconstitute, and can be 
manufactured in large quantities (Spier, 1996). 
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Likewise, according to Abdelnoor, plasmid DNA does not contain heterologous 
protein components to which the host may respond (Abdelnoor, 2001) and has the 
capacity to induce in vivo expression of antigens conserving the native confirmation of 
epitopes (Abdelnoor, 2001). Conservation of the native confirmation of epitopes is 
important for the induction of specific antibodies and cellular responses (Abdelnoor, 
2001). Plasmid DNA may include more than one immunogene and will have the 
advantage of potentially decreasing the number of vaccinations required in children 




MATERIALS AND METHODS 
 
3.1 Growth and amplification of virus: 
 
A standard embryonated chicken egg inoculation method as described by Mahy 
and Kangro was used for virus cultivation (Mahy and Kangro, 1996). Equine-2 influenza 
virus, A/Eq/KY/98 was grown in 10-12 day old embryonated chicken eggs at 370C for 72 
hrs. and extracted from an allantoic fluid. The allantoic fluid was harvested as described 
by Mahy and Kangro (Mahy and Kangro, 1996). After clarification by centrifugation at 
1000g for 15 minutes, a hemagglutination assay was used to determine the virus titer.  
 
3.2 Hemagglutination assay: 
 
A standard method of hemagglutination assay was followed as described by 
Barrett and Inglis (Barrett and Inglis, 1985). After clarification of virus, the 
hemagglutinin assay was determined using serial dilutions of sample and mixing it with 
1% chicken red blood cells in a hemagglutinin assay plate. The plate was observed for 
hemagglutination after 30 minutes incubation at room temperature and virus titer was 
determined. 
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3.3 Selection of DNA vaccines: 
 
Two DNA vaccines pTOPOKY98#6 and pVAXKY98/11-9 were used for 
immunization in Balb/c mice. The DNA vaccines were designed and characterized by Lai 
et al (unpublished data). Two mammalian expression vectors pcDNA3.1/V5/His 
(pTOPOV5/His) and pVAX1 (Invitrogen, CA) were used for construction of DNA 
vaccines.  
 
As reported in its manual: “pcDNA3.1/V5/His is a 5.5 kb plasmid vector and has 
multiple TOPO cloning sites. It consists of pCMV and T7 promoters, V5 epitope and C-
terminal polyhistidine tag, BGH reverse priming site, BGH polyadenylation signal, SV40 
early promoter & origin, neomycin resistance gene and ampicillin resistance gene”
(Invitrogen, pcDNA3.1-TOPO TA expression Kit, 2004). 
 
Similarly, according to its manual: “pVAX1 is a 3.0 kb plasmid vector and 
specially designed for development of DNA vaccines. It is a derivative of 
pcDNA3.1/V5/His with reduced size and replacement of ampicillin resistance gene by 
kanamycin resistance gene” (Invitrogen, pVAX1, catalog no. V260-20, version B) 
 
3.3.1 Construction of DNA vaccine pTOPOKY98#6:  
 
The DNA vaccine pTOPOKY98#6 was prepared by Lai et al. The HA1 gene of 
equine-2 influenza virus was cloned into the vector pTOPOV5/His by two different ways. 
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One clone was prepared without a 3’ stop codon, and its open reading frame (ORF) was 
in frame with the C terminal His tag. The second clone was prepared by using 3’ stop 
codon. 
 
In this study, the clone prepared without a 3’ stop codon was used as a DNA 
vaccine, designated as pTOPOKY98#6. One shot competent E. coli cells supplied by the 
manufacturer (Invitrogen, CA) were transformed with the pTOPOKY98#6. Clones were 
selected for the presence of ampicillin resistance. These clones were constructed and 
characterized by Lai et al. 
 
3.3.2 Construction of DNA vaccine pVAXKY98/11-9: 
 
The DNA vaccine pVAXKY98/11-9 was prepared by Lai et al. The HA1 gene in 
pTOPOKY98/11-9 was cut using restriction enzyme HindIII and BstX1. The gene was 
ligated into eukaryotic expression vector pVAX1 according to the manufacturer’s 
instruction (Invitrogen, CA). The clone was designated as pVAXKY98/11-9. These 
clones were constructed and characterized by Lai et al (unpublished data). As described 
previously, these clones were further characterized in vitro, for use as a DNA vaccine for 
equine influenza virus. 
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3.4 Extraction of plasmid DNA: 
 
For extraction, DNA constructs were amplified in Escherichia coli. After 
amplification, DNA was extracted using a MaxiPrep plasmid DNA isolation method and 
subjected to restriction digestion and PCR for verification of the presence of the insert.  
 
3.5 DNA band with Restriction digestion: 
 
The different combinations of restriction enzymes such as HindIII and PstI, 
HindIII and XhoI and HindIII and XbaI were used for restriction digestion. The 




Plasmid DNA 10.0 µl
Reaction buffer 2.0 µl
HindIII 0.5 µl
PstI (or XhoI or XbaI) 0.5 µl
Distilled water 7.0 µl
Table 3-1: Chemicals for restriction digestion 
 
Ten µl of DNA was taken in an eppendorf tube and 0.5 µl of HindIII, 0.5 µl of
PstI (or XhoI or XbaI), 2.0 µl of reaction buffer and 7.0 µl of distilled water were added 
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to it to make a total reaction volume of 20.0 µl. The mixture was incubated for 2 hours on 
water bath at 370C. 
 
The agarose gel electrophoresis was used for confirmation of insert in digested 
DNA. For that, 5 µl of digested DNA was mixed with 1 µl of blue tracking dye and 
loaded on a 1.5% agarose gel. The gel was run for 20 minutes at 100 V in TBE buffer. 
The gel was stained with ethidium bromide (1.0 µg/ml) for 10 minutes. The gel was 
visualized and the presence of DNA fragments was confirmed. 
 
3.6 Confirmation of insert by PCR: 
 
The lyophilized 2X Master Mix buffer (Promega, Wisconsin) was prepared by Lai 
et al. (Lai et al., 2001) to a volume of 17.0 µl with nuclease free water. Master mix buffer 




Taq DNA polymerase 50 units/ml (pH 8.5) 
dNTPs (dATP, dGTP, dCTP, dTTP) 400 mM 
Tris HCl  50.0 mM (pH 9.0) 
MgCl2 3.0 mM 
Nuclease free water To a volume of 17.0 µl
Table 3-1: Chemicals used for preparation of PCR 2X Master mix buffer 
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PCR was performed using 17.0 µl of 2X Master mix buffer and using 1.0 µl of





Plasmid DNA 1.0 µl
Forward primer (T7 specific) 1.0 µl
Reverse primer  1.0 µl
Master Mix buffer  17.0 µl
Table 3-3: preparations for PCR 
 
The different combinations of 1.0 µl of forward primers (forward primer specific 
to T7, EH3 451+) and 1.0 µl of reverse primers (EH3 450-, EH3 1061- and EH3 832-) were 
added to the tube to make a total volume of 20 µl. The PCR conditions provided were;  
denaturation at 950C for 30 seconds, annealing at 420C for 30 seconds, extension at 720C
for one minute for a total of 30 cycles using a PCR thermocycler (Perkin, California). 
The presence of the DNA fragment was confirmed by agarose gel electrophoresis. 
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3.7 Transfection of HA in cell cultures: 
 
In transfection experiments, two cell cultures, Vero cells and MDCK cells were 
used for expression of HA in tissue transfection and in-vitro protein expression. For cell 
culture, Dulbecco’s modified Eagle’s medium (DMEM) was used and antibiotics such as 
ampicillin, streptomycin and amphotericin (Cellgro, Virginia) were added to the medium. 
The standard cell culture method as described by George et al. (George et al., 1996) with 
some modifications was followed.  
 
3.7.1 Transfection by lipofection: 
 
Lipofection was used to transfect Vero cells and MDCK cells with designed DNA 
plasmids utilizing lipofectin. About eighty percent confluent cell cultures were used for 
transfection. Lipofection was performed for transfection of HA genes as follows; 
 
a). Preparation of cell culture: 
 
Cell culture plates were washed with 1x PBS and 1 ml of Trypsin-EDTA was 
added. Cells were incubated in a CO2 incubator for 10 minutes. About 0.5 ml of cells 
were passed into 35 mm petri-dishes and 5 ml of DMEM with 5% fetal bovine serum 
(FBS) was added. The plates were incubated overnight in a CO2 incubator. The 
Following day, cells were resuspended to 3-5 x 105 cells/ml.  
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b). Preparation of DNA-liposome mixture: 
 
Two hundred µl serum free DMEM was placed in three separate tubes and 2.0 µl
of pTOPOKY98, pVAXKY98 or pGFP DNA were added to tubes separately. Twenty-
four µl of lipofectin was added to 600 µl of serum free DMEM in a separate tube and 
mixed well. Then, 200 µl of this solution was added to each of the DNA tubes. DNA-
liposomes mixtures were prepared and incubated at room temperature for 30 minutes.  
 
c). Transfection of DNA into cell cultures: 
 
The DNA-liposome mixtures were transferred onto a monolayer of Vero cells and 
MDCK cells in a 35 mm Petri-dish separately after washing with 1x PBS. Six hundred µl
of serum-free DMEM medium was added to each petri-dish separately. The plates were 
incubated for 7 hours in a CO2 incubator and 1.0 ml DMEM containing 10% FBS was 
added to them. The plates were further incubated overnight in a CO2 incubator. 
 
d). Extraction of cells: 
 
After overnight incubation, the resulting monolayer of cells was scraped and 
detached with the help of a sterilized rubber policeman. Cells were washed three times in 
PBS, and re-suspended in hypotonic saline solution (0.9%) for 10 minutes. The cells were 
centrifuged at 1000g for 1.0 minute and the supernatant was collected as the cytosol 
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fraction. The pellet was resuspended in sterile distilled and deionized water (ddH2O), and 
centrifuged at 1000g for 1.0 minute and the supernatant was collected as the nuclear 
fraction. ELISA and PCR were performed for HA expression protein using both cytosolic 
and nuclear fractions to verify the presence of the DNA as a measure of transfection.  
 
3.7.2 Transfection by electroporation: 
 
Electroporation is the transfection of cells with plasmid utilizing electric current. 
Electroporation methods were adopted from methods as described by Chu et al with 
modifications (Chu et al., 1987). Electroporation was performed as follow: 
 
a). Preparation of cell culture: 
 
Cell cultures were prepared following the same way as with lipofection above. 
About eighty percent confluent Vero cells and MDCK cells were harvested by washing 
the cell sheet with PBS, and incubating at 370C for ten minutes after addition of 0.5 ml of 
Trypsin-EDTA. The cells were collected into a sterile 5 ml tube and washed with PBS 
three times by centrifugation at 500g for 1.0 minute. They were re-suspended to 2-5 x 106
cells/ml in DMEM without serum.  
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b). Preparation of DNA for eletroporation: 
 
The cell suspension in DMEM was distributed in 400 µl volumes in three 
eppendorf tubes. Twenty µl of purified plasmid DNA, pTOPOKY98, pVAXKY98 and 




A BTX electroporator (BTX-ECM 39, Genetronic) was used for transfection of 
the DNA preparation. The DNA mixture was added into electroporation cuvettes and 
pulsed in electroporator providing the following conditions: 260 V, 1050 µF, and 29 




3.8 Mice vaccination study: 
 
3.8.1 Design and schedule: 
 
Mice vaccination and virus challenge study were performed in the Animal 
Laboratory Facilities, Center for Veterinary Health Sciences, Oklahoma State University, 
March-May, 2004. Seven groups of five, 4-8 weeks old female Balb/c mice were selected 





Commonly used name  
Group 1 negative control group (PBS only) unvaccinated group 
Group 2 positive control group (UV-inactivated KY98) Inactivated group 
Group 3 vaccinated group (pTOPOKY98#6, Liposome) pTOPO (L) group 
Group 4 vaccinated group (pTOPOKY98#6, MetaStim) pTOPO (M) group 
Group 5 vaccinated group (pVAXKY98/11-9, Liposomes) pVAX (L) group 
Group 6 vaccinated group (pVAXKY98/11-9, MetaStim) pVAX (M) group 
Group 7 non-related plasmid DNA group (pGFP, liposome) pGFP group  






Day 0 Body weight measurement,   
Serum collection and vaccination 
Day 21 Body weight measurement,  
Serum collection and booster vaccination 
Day 42 Body weight measurement,  
Serum collection and Virus challenge 
Day 49 (from day 42 to 49) Body weight measurement daily for 7 days, 
serum collection at 7 days post infection 
Day 52 Serum collection and Euthanasia 
Table 3-5: Table showing schedule of the vaccination and virus challenge  
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3.8.2 Mice vaccination: 
 
The following vaccination protocols were used for delivering DNA vaccines in 
mice: 
 
a). Vaccine dosage:  
 
A vaccine dosage of 25µl dose/mouse containing 0.01 µg DNA per gram body 
weight was designed. Before vaccination, the DNA preparation diluted in DMEM to 20 
µg/ml and lipofectamine in DMEM (20µg/ml) were mixed and allowed to stand at room 
temperature for 20 minutes. Twenty five µl of respective preparation of DNA was 
inoculated per nostril intranasally to each mouse of vaccinated groups. 
 
b). Intranasal inoculation: 
 
For mice groups 3 to 6, vaccination was performed following intranasal 
inoculation with the designed primary dose of the respective preparation of DNA 
vaccines on day 0. A booster dose was given on day 21 following the same route and 
dose.  
 
For the unvaccinated group, 25 µl of PBS was administered per nostril 
intranasally. For the inactivated or positive control group, the uv-inactivated A/Eq/Ky/98 
virus was administered intranasally. The inactivated virus preparation was prepared from 
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an allantoic fluid culture of A/Eq/Ky/98 virus with a HA titer of 1:16. The virus was 
inactivated by exposure to ultra-violet radiation by placing 1.0 ml of the virus suspension 
in a petri-dish, without a lid, at a distance of 15 inches from a 30 W UV lamp, for 15 
minutes. This method was adapted from the methods of Ramamoorthy (Ramamoorthy, 
2001). 
 
c). Virus challenge: 
 
On day 42, all groups of mice were challenged with homologous A/Eq/Ky/98 
virus with a HA titer of 16 HA units by intranasal inoculation of 25 µl per nostril. The 
mice body weights were recorded on day 0, 21, 42 before challenge and everyday after 
challenge for 10 days. All mice were bled on the 7th day post challenge for serum 
collection and euthanized on the 10th day using isofluorane as anesthesia, followed by 
cervical dislocation. 
 
d). Serum collection: 
 
A retro-orbital bleeding method was used to collect blood from mice. The 
procedures were carried using Isofluorane (Fluorane,1-chloro-2, 2, 2-
trifluoroethyldifloromethyl ether) anesthesia. In a closed glass jar, a cotton pad soaked 
with 0.5 ml of 2 % isofluorane was placed and mice were held until loss of pedal and 
ocular reflexes occured. For that an average time of one and a half minutes was allowed. 
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The blood samples were collected during the time period when mice had the effect of 
anesthesia.  
 
3.9 ELISA for viral specific IgG and IgA titers: 
 
ELISA methods were adopted from Deck et al (Deck et al., 1997) with the 
following modifications performed in the following steps: 
 
a). Coating of ELISA plates: 
ELISA plates (Nalge Nunc, NY) were coated with a suspension of purified 
influenza virus. The virus was diluted in 50mM NaHCO3 solution to 0.6 HA units/ml, 
and 100 µl of this virus suspension was added to each well of the ELISA plate. The plates 
were left at room temperature for 24 hours for the antigen to be coated onto the plate.  
 
b). Blocking buffer: 
Before using blocking buffer, the plates were washed three times with 1x PBS. A 
blocking buffer (PBS containing 2% BSA and 0.5% skim milk) was prepared and 100 µl
of blocking buffer was added to wells of the ELISA plates. Plates were incubated at room 
temperature for 1 hour.  
 
43
c). Addition of primary antibody: 
The different dilutions of mouse serum (1:25, 1:50, 1:100 and 1:200) were 
prepared in PBS with 2% BSA and 100 µl of diluted serum was added in triplicate to 
plates. The plates were washed three times again with 1x PBS before adding primary 
antibody. The plates were incubated at room temperature for 1 hour.  
 
d). Addition of secondary antibody: 
The 1:2000 dilutions of anti-mouse IgG and IgA conjugate (Chemicon, CA) were 
prepared and 100 µl of each preparation was added to the plates in the respective wells 
after washing the plates three times with 1x PBS. The plates were incubated at room 
temperature for 1 hour.  
 
e). Addition of substrate: 
1 mg/ml of pNPP (p-nitrophenyl phosphate, Sigma, MO)) was prepared in glycine 
buffer and used as a substrate. After incubation, the plates were washed with 1x PBS 
three times and 100 µl of substrate was added. The plates were incubated for two and a 
half hours at room temperature. 
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f). Serum titers: 
After incubation, O. D. readings were taken at 405 nm using the ELISA plate 
reader (Biotek Instruments). Mice serum titer observed on day 0 was used as a normal 
sera titer. Titers were expressed as the mean of triplicates after subtracting the blank 
(control) and normal sera titer.  
 
3.10 Statistical analysis: 
 
Statistical analysis was carried out using the SAS program and the PROC GLM 
procedure for ANOVA (Analysis of Variance) (SAS Institute, 2004). The graph 
construction was carried out using the Sigma-plot program (SigmaPlot, 2004). The 
standard error of the mean was obtained and represented graphically. A Dunett’s t test 
was performed on the challenge experiment and ELISA data and levels of significance 






4.1 Confirmation of insert in DNA vaccine constructs: 
 
Two DNA vaccine vectors pTOPOKY98#6 and pVAXKY98/11-9 used in the 
vaccination experiment were characterized by PCR and restriction digestion experiments. 
They were validated for the HA gene insert, and its orientation. By performing the PCR 
and restriction digestion, a correct size of insert and correct orientation was observed in 
the pTOPOKY98#6 and pVAXKY98/11-9 vectors as shown in figure 4-1 and 4-2. 
 
4.1.1. Confirmation by restriction digestion: 
 
The orientations of insert are given in Fig 4-1 and 4-2, photographs of agarose 
gels with restriction digestion samples of vectors pTOPOKY98 and pVAXKY98. The 1.0 
kb band in the sample lanes 1 and 2, digested with two HindIII and PstI and HindIII and 
XhoI restriction enzymes, indicates that the 1 kb HA1 fragment was correctly inserted 
into the vector. 
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Fig 4-1: Restriction digestion and PCR of pTOPOKY98#6: Lane *: 1 Kb DNA ladder; Lane 1: HindIII + 
PstI; Lane 2: HindIII + XhoI; Lane 3: HindIII + XbaI; Lane 4: forward primer specific to T7 promoter + 
EH3 450-; Lane 5: T7 plus EH3 1061-; Lane 6: EH3 451+ + EH3 1061- and Lane 7: EH3 451+ + EH3 832-
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Fig 4-2: Restriction digestion and PCR of pVAXKY98/11-9: Lane *: 1 Kb DNA ladder; Lane 1: HindIII + 
PstI; Lane 2: HindIII + XhoI; Lane 3: HindIII + XbaI; Lane 4: forward primer specific to T7 promoter + 
EH3 450-; Lane 5: T7 plus EH3 1061-; Lane 6: EH3 451+ + EH3 1061- and Lane 7: EH3 451+ + EH3 832-
48
4.1.2 Confirmation by PCR: 
 
The PCR method was used for verification of the orientation of the insert in DNA 
construct. The orientation was verified using a forward primer specific to the 5’ T7 
promoter and a reverse primer specific to an internal site 415 bps down stream of the HA 
gene. The expected product was found as seen lanes 6 and 7 as shown in Fig. 4-1. 
 
4.1.3 PCR for transfected HA: 
 
The PCR was used for cytosol and nuclear fractions from cell cultures transfected 
with pTOPOKY98#6 and pVAXKY98/11-9. For this experiment, a forward primer EH3
29+ and a reverse primer EH3 1061- were used. The expected 1kb bands were not 
observed, however HA expression proteins were detected by ELISA (data not shown). 
The plasmid pGFP was used as a negative DNA control (figure not shown).  
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4.2 Mice vaccination study: 
 
A weight loss model was designed in mice to evaluate the effectiveness of 
vaccination. The body weight of each mouse was taken daily after virus challenge and the 
results were expressed as the percentage change in body weight after challenge. The body 
weight of each mouse on the day of virus challenge was considered as day 0 body weight. 
The graphs are made plotting mean weight loss in each group with the standard error of 
the mean (SEM) against the days after challenge as shown in Fig. 4-3. 
 
a). Disease symptoms: 
 
After virus challenge, mice were observed for clinical symptoms for next ten days 
to determine the severity of disease in each group. The prominent “fluffy coat” 
appearance and inactivity were observed in the unvaccinated group mice for 3 days after 
virus challenge and they took longer time for recovery. A lesser severity of disease was 
observed in the vaccinated group mice in comparison to the unvaccinated mice and found 
that they recovered more quickly. Likewise, similar symptoms were observed in the 
pGFP group as found in the unvaccinated mice group but recorded a lesser weight loss 
than that of the unvaccinated group. The symptoms were found for a longer period than 
the vaccinated groups and almost similar to the unvaccinated group.  
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b). Weight loss result: 
 
A maximum of 8.4% mean body-weight loss on day 3 was recorded in the 
unvaccinated group mice and they did not recover the initial body-weight for more than 7 
days. Maxima of 1.2% and 0.82% body weight losses were observed in pTOPOKY98 
and pVAXKY98 vaccinated group mice which were significantly different from the 
unvaccinated group mice.  
 
Likewise, a maximum of 6.5% weight loss on day 3 in the pGFP group mice was 
recorded that is still less than that of the unvaccinated group. As symptoms were found 
for a longer period than the vaccinated groups and almost similar to the unvaccinated 
group; it is believed that this type of observation is due to the nonspecific protection 
elicited by the DNA vaccine.  
 
c). Statistical significance of weight loss model: 
 
The body weight loss in the vaccinated groups was found to be significantly 
different from that unvaccinated group (P<0.001). The pGFP group showed no 
significant difference with a P value of 0.23. There were no significant differences 
observed between the vaccinated groups pTOPOKY98 and pVAXKY98 (p=0.67); 
likewise no significant differences were observed between liposome and metastim 




4.3.1 Viral specific IgG (mean O.D.) value: 
 
The mice sera were collected at day 0, 21, 42 and 49 (day 7 post-infection) and 
these samples were assayed for virus-specific IgG mean O.D. value. An increased 
optimal density (O.D.) at 405nm was observed in sera after vaccinations and expressed as 
the mean of triplicates after subtracting the blank (control) and normal sera titer. The 
different dilutions 1:25, 1:50, 1:100 and 1:200 of the sera were used to assay the virus-
specific IgG titers and found that 1:25 dilution was found to provide an optimal O.D. 
value. The mean IgG titers are given in Table 4-1 and plotted in Fig 4-5, 4-6, 4-7 and 4-8.  
 
a). Observation of IgG (mean O. D.) value on day 21: 
 
A mean O.D. increase of 0.43 (p<0.01) units above normal serum was observed 
in the inactivated group. In pTOPO (L) and pTOPO (M) groups, an increase of 0.36 
(p<0.01) and 0.43 (p<0.01) O. D. units were observed respectively whereas in pVAX (L) 
and pVAX (M) groups, an increase of 0.40 (p<0.01), and 0.49 (p<0.01) O.D. units, were 
recorded respectively. An increase of 0.20 (p = 0.70) was observed in the pGFP group. 
On day 21, the vaccinated groups and the inactivated group showed significant increase 
in titers when compared to the unvaccinated group.  
b). Observation of IgG (mean O.D.) value on day 42: 
 
An increased of 0.72 (p<0.01) O.D. units was recorded in the inactivated group. 
In pTOPO (L) and pTOPO (M) groups, an increase of 0.52 O.D. units (p<0.01), and 0.88 
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O.D. units (p<0.01) were recorded respectively. Whereas, for the pVAX (L) and pVAX 
(M) groups, an increase of 0.59 (p<0.01) and 0.72 (p<0.01) O. D. units were recorded 
respectively. No significant increase for the pGFP group (p=0.69) was recorded. The 
output of statistical analysis is given in Appendix-B. 
 
On day 42, the vaccinated groups and the inactivated group showed significant 
increase in titers compared to the unvaccinated groups. Significant differences were 
observed between two different vaccinated groups pTOPO and pVAX on day 42 and 49 
(p<0.01) while marginal difference was observed on day 21 (p=0.049). Likewise 
significant differences were observed between liposome and metastim treatment groups 
on day 42 and 49 for pTOPO (p<0.01) and on day 21, 42 and 49 for pVAX (p<0.01). 
 
c). Observation of IgG (mean O.D.) value after virus challenge: 
 
On day 49 (day 7 post infection), an increase of 1.4 O.D. (p<0.01) units was 
recorded in the inactivated group. In pTOPO (L) and pTOPO (M) groups, an increase of 
1.0 (p<0.01) and 1.2 (p<0.01) O.D. units were recorded respectively. Similarly, in pVAX 
(L) and pVAX (M) groups; an increase of 1.1 (p<0.01) and 1.76 (p<0.01) O.D. units were 
recorded respectively. The titers of the unvaccinated group and the pGFP groups were 




Virus specific IgG as measured by ELISA 
 
Group Day 
IgG titer (Mean O. D. +/- SEM)  
(Dilution: 1:25) 
Day 21 0.22 (+/- 0.016) 
Gr-1 Day 42 0.22 (+/- 0.037) 
unvaccinated mice Day 7 post infection 0.66 (+/- 0.071) 
Gr-2 Day 21 0.43 (+/- 0.042) 
Inactivated group Day 42 0.72 (+/- 0.077) 
Day 7 post infection 1.42 (+/- 0.289) 
Gr-3 Day 21 0.36 (+/- 0.044) 
pTOPO (L) Day 42 0.52 (+/- 0.014) 
Day 7 post infection 1.01 (+/- 0.110) 
Gr-4 Day 21 0.43 (+/- 0.006) 
pTOPO (M) Day 42 0.88 (+/- 0.159) 
Day 7 post infection 1.28 (+/- 0.263) 
Gr-5 Day 21 0.40 (+/- 0.162) 
pVAX (L) Day 42 0.59 (+/- 0.073) 
Day 7 post infection 1.11 (+/- 0.076) 
Gr-6 Day 21 0.49 (+/- 0.017) 
pVAX (M) Day 42 0.72 (+/- 0.078) 
Day 7 post infection 1.76 (+/- 0.331) 
Gr-7 Day 21 0.20 (+/- 0.069) 
pGFP Day 42 0.21 (+/- 0.033) 
Day 7 post infection 0.74 (+/- 0.156) 
Table 4-1: Table showing viral specific IgG (mean O.D.) value for each group with SEM (standard error of 
the mean) after vaccinations and virus challenge. Mean O.D. and SEM were obtained using Sigma Plot, 
2004. (Refer to Table 3-4 for abbreviation). 
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Fig 4-5: Viral specific IgG (mean O.D.) value as measured by ELISA. (uv-ky98: Inactivated group, pGFP: 
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Fig 4-6: Viral specific IgG at day 21 as measured by ELISA using serum dilutions  








virus specific IgG at day 42 as measured by ELISA 












Fig 4-7: viral specific IgG at day 42 as measured by ELISA using serum dilutions  
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Fig 4-8: Viral specific IgG at 7 days post-challenge as measured by ELISA using serum dilutions  
 (1:25, 1:50, 1:100, 1:200) 
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4.3.2 Viral specific IgA (mean O.D.) value: 
 
The mice sera were collected on day 0, 21, 42 and 49 (day 7 post-infection) and 
these samples were assayed for virus-specific IgA titers. An increased optimal density 
(O.D.) at 405nm in sera was observed after vaccinations and is expressed as the mean of 
triplicates after subtracting the blank and normal sera titer. The different dilutions 1:25, 
1:50, 1:100 and 1:200 of the sera were used to assay the virus-specific IgA titers. The 
mean IgA titers are given in Table 4-2 and plotted in Fig 4-9, 4-10 and 4-11.  
 
a). Observation of IgA (mean O.D.) value on day 21: 
 
A mean O.D. increase of 0.21 (p<0.01) units above the normal value was 
observed in the inactivated group. In pTOPO (L) and pTOPO (M) groups; an increase of 
0.21 (p<0.01) and 0.22 (p<0.01) O. D. units were recorded respectively whereas in 
pVAX (L) and pVAX (M) groups; an increase of 0.23 (p<0.01), and 0.25 (p<0.01) O.D. 
units were recorded respectively. An increase of 0.18 (p = 0.0023) was recorded in the 
pGFP group. On day 21, the vaccinated groups and the inactivated group showed 
significant increases in mean O.D. values when compared to the unvaccinated groups. 
 
b). Observation of IgA (mean O.D.) value on day 42: 
 
An increase of 0.38 (p<0.01) O.D. units was recorded in the inactivated group. In 
pTOPO (L) and pTOPO (M) groups; an increase of 0.41 O.D. units (p<0.01), and 0.44 
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O.D. units (p<0.01) were recorded respectively. Whereas, in pVAX (L) and pVAX (M) 
groups; an increase of 0.58 (p<0.01) and 0.59 (p<0.01) O. D. units were recorded 
respectively. No significant increase in the pGFP group (p=0.079) was observed. The 
output of statistical analysis is given in Appendix-C. 
 
On day 42, the vaccinated groups and the inactivated group showed significant 
increases in mean O.D. values when compared to the unvaccinated groups. No significant 
differences were observed between two different vaccinated groups pTOPO and pVAX; 
likewise no significant differences were observed between liposome and metastim 
treatment groups. 
 
c). Observation of IgA (mean O.D.) values after virus challenge: 
 
On day 49 (day 7 post infection), an increase of 0.99 O.D. (p<0.01) units was 
observed in the inactivated group. In pTOPO (L) and pTOPO (M) groups; an increase of 
0.72 (p<0.01) and 0.79 (p<0.01) O.D. units were recorded respectively. Similarly, in 
pVAX (L) and pVAX (M) groups; an increase of 0.79 (p<0.01) and 0.80 (p<0.01) O.D. 
units were recorded respectively. The mean O.D. values of the unvaccinated group and 





Virus specific IgA as measured by ELISA 
 
Group Day 
IgA titer (Mean O. D. +/- SEM) 
Dilution (1:25) 
 
Day 21 0.19 (+/- 0.023) 
Gr-1 Day 42 0.21 (+/- 0.042) 
unvaccinated mice Day 7 post infection 0.48 (+/- 0.071) 
Gr-2 Day 21 0.21 (+/- 0.022) 
Inactivated group Day 42 0.38 (+/- 0.052) 
Day 7 post infection 0.99 (+/- 0.326) 
Gr-3 Day 21 0.21 (+/- 0.033) 
pTOPO (L) Day 42 0.41 (+/- 0.012) 
Day 7 post infection 0.72 (+/- 0.182) 
Gr-4 Day 21 0.22 (+/- 0.005) 
pTOPO (M) Day 42 0.44 (+/- 0.124) 
Day 7 post infection 0.79 (+/- 0.223) 
Gr-5 Day 21 0.23 (+/- 0.112) 
pVAX (L) Day 42 0.58 (+/- 0.089) 
Day 7 post infection 0.79 (+/- 0.308) 
Gr-6 Day 21 0.25 (+/- 0.028) 
pVAX (M) Day 42 0.59 (+/- 0.062) 
Day 7 post infection 0.80 (+/- 0.221) 
Gr-7 Day 21 0.18 (+/- 0.069) 
pGFP Day 42 0.19 (+/- 0.044) 
Day 7 post infection 0.55 (+/- 0.144) 
Table 4-2: Table showing viral specific IgA (mean O. D.) value for each group with SEM (standard error of 
the mean) after vaccinations and virus challenge. Mean O. D. and SEM were obtained using Sigma Plot, 
2004. (Refer to Table 3-4 for abbreviation). 
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Virus specific IgA as measured by ELISA




















Fig 4-9: Viral specific IgA (mean O.D.) values as measured by ELISA. (uv-ky98: Inactivated group, pGFP: 




Viral specific IgA at day 21 as measured by ELISA


















Fig 4-10: Viral specific IgA at Day 21 measured by ELISA using serum dilutions  
 (1:25, 1:50, 1:100, 1:200) 
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Fig 4-11: Viral specific IgA at Day 42 as measured by ELISA using serum dilutions  
 (1:25, 1:50, 1:100, 1:200) 
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CHAPTER 5 




The objective of this study was to evaluate the effectiveness of designed DNA 
vaccines pTOPOKY98#6 and pVAXKY98/11-9 in eliciting protective immunity in mice. 
In this study, the levels of serum antibody after vaccination and weight loss after virus 
challenge were studied, and it was found that after two intranasal vaccinations with 
designed DNA vaccines pTOPOKY98#6 and pVAXKY98/11-9, a significant increase of 
serum antibody levels was found in the vaccinated mice as shown in Fig. 4-5 and 4-9.  
 
In this study, it was found that designed plasmids encoding the HA1 gene were 
effective in generating immune responses in mice. Several studies conducted by Fynan et 
al., Montgomery et al., Robinson et al., Bot et al., Kodihalli et al. and Johnson et al. 
reported that an HA expressing plasmid could induce protective immunity against 
influenza (Fynan et al., Montgomery et al., Robinson et al., 1993, Bot et al., 1997, 
Kodihalli et al., 1999; Johnson et al., 2000).  
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In the study of Fynan et al., it was reported that the plasmid DNA expressing HA 
protein using different routes of inoculation could initiate protective immunity in mice 
(Fynan et al., 1993). It was also reported that the DNA quantity required was less in 
mucosal routes like trachea or nares and was successful in inducing protection. Similarly, 
in the study of Wong et al, intranasal delivery of viral HA in liposome was found to 
provide protection, and both serum IgG and IgA were found (Wong et al., 2001).  
 
Similarly, it was reported by Bot et al. that a plasmid bearing a HA gene was 
successful in generating protective immune responses in newborn and adult mice (Bot et 
al., 1997). In their study, mice survival was significantly increased after immunization.  
Likewise, it was reported by Johnson et al. that direct intramuscular injection of plasmid 
DNA induced Th1 responses and a high level of protection against live influenza virus 
challenge. It was reported by Kodihalli et al. that a DNA vaccine encoding HA provided 
immunity against highly virulent equine virus H5N1 infection in mice. 
 
In this study, it was found that the expression of HA1 alone is sufficient to elicit 
protective immunity, which is in accordance to findings of Ramamoorthy, and Tonegawa 
et al (Ramamoorthy, 2001; Tonegawa et al., 2003). It was reported by Ramamoorthy that 
a protective immunity was observed in mice using pTOPOKY98 expressing HA1 from 
equine-2 influenza virus (Ramamoorthy, 2001). The increased levels of serum IgG and 
IgA titers were also found in the vaccinated mice. Similarly, in the study of Tonegawa et 
al., mice were immunized with HA1 DNA and a humoral response was observed after 
immunization and an increased survival rate was also found against homologous virus 
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challenge. However, the gene gun method was used in delivering DNA. It is expected 
that using an HA1 segment instead of full length HA gene in the DNA vector, will 
facilitate the release of HA1 protein in host cells because it will not be membrane bound 
in the absence of HA2. This will help to elicit better immunity and a lower dose of DNA 
will be sufficient to generate protective immunity (Ramamoorthy, 2001).  
 
In this study, it was found that dose levels as low as 0.01 µg DNA/gram body-
weight were sufficient to elicit protective immunity in mice. In the study of Fynan et al., 
it was reported that as little as 0.4 µg of DNA was sufficient to provide protection in mice 
(Fynan et al., 1993). The DNA dose used in this study is less than that employed in the 
study of Fynan et al. Similarly, it was reported by Robinson et al. that a primary dose of 
0.04 µg of DNA and a booster dose of 0.004 µg of DNA were sufficient to provide 
protection against lethal viral challenge (Robinson et al., 1997). The primary dose used 
was somewhat similar to this study while the booster dose was less in the study of 
Robinson et al., however, gene gun was the delivery method in that study. In the study of 
the Tonegawa et al., it was reported that 0.006 µg dose of HA while using #1HA1 DNA 
and less than 0.06 µg dose of HA while using #2HA1 DNA were sufficient to induce 
humoral immunity and provide increased survival of mice. The DNA dose used in this 
study is nearly similar to that of the Tonegawa et al. study while using #2HA1; however 
the gene gun was the method of delivery in their study also.  
 
It was found that intranasal immunization using these DNA vaccines elicits 
specific IgG and IgA antibodies to the HA1 protein. Previous studies have shown that 
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mucosal immunity is important in protection against influenza virus and other respiratory 
infections (Liew et al, 1984; Ada et al., 1986; Fynan et al., 1993; Lunn et al., 1999). It 
was reported by Liew et al. that IgA is responsible for protection against influenza virus 
infection (Liew et al., 1984). In the study of Lunn et al., it was reported that delivery of 
an HA encoding plasmid at skin and mucosal sites in ponies was found to stimulate IgG 
responses and a poor IgA response (Lunn et al,. 1999).  
 
Many studies have shown that intranasal inoculation of a DNA vaccine for 
influenza virus can elicit protective immunity in mice (Fynan et al.; Wong et al, 2001, 
1993, Ramamoorthy and Lai, 2001). In the study of Fynan et al., it was reported that 95% 
protection was found in mice after mucosal routes of immunization like trachea and 
nares. Likewise in the study of Wong et al., it was reported that intranasal delivery of 
DNA by liposomes induced protective mucosal immunity in the respiratory tract. It was 
reported by Ramamoorthy that intranasal inoculation of plasmid DNA induced protective 
immunity in mice (Ramamoorthy, 2001). It has been found that specialized lymphoid 
tissues known as MALT (mucosa-associated lymphoid tissues) and NALT (nasal-
associated lymphoid tissue) are very much similar in all vertebrates. It is expected that 
these lymphoid tissues will function in the same way in horses in eliciting protective 
immunity against influenza infections.  
 
In this study, it was also found that two intranasal inoculations were significantly 
better than one inoculation. As reported earlier by Ramamoorthy, a second booster did 
not result in an increase in the titers of viral specific IgG or IgA and was not necessary 
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(Ramamoorthy, 2001). Protective immunity was observed in mice by encapsulation of 
the DNA vaccine into liposome and metastim and by delivering the DNA vaccine 
intranasally. The protection is probably mediated by IgA and IgG as there was a 
significant increase of viral specific IgA and IgG in serum after the first booster 
vaccination.  
 
In this study, no significant differences were observed between two different 
vaccinated groups pTOPOKY98 and pVAXKY98 (p=0.67) while using the weight loss 
model after virus challenge. Similarly, no significant differences were observed between 
liposome and metastim treatment groups (p=0.30) for the weight loss model. In the case 
of IgG levels, significant differences were observed between two different vaccinated 
groups pTOPO and pVAX on day 42 and 49 (p<0.01) while a marginal difference was 
observed on day 21 (p=0.049). IgG mean O.D. values were comparatively higher in the 
pVAX group than the pTOPO group on day 21, 42 and 49. Likewise significant 
differences were observed for the liposome and the metastim treatment groups on day 42 
and 49 for the pTOPO (p<0.01) and on day 21, 42 and 49 for the pVAX (p<0.01). IgG 
mean O.D. values were slightly higher in the metastim group than the liposome group. 
While in the case of IgA levels, no significant differences were observed between two 
different vaccinated groups pTOPO and pVAX; likewise no significant differences were 
observed between liposome and metastim treatment groups. A possible explanation for 
the high mean O.D. value of IgG is due to anamnestic responses after booster 
vaccinations. The increase in mean O.D. values of IgA was not very high even after 
booster vaccination in comparison to IgG titer. 
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The continuous emergence of new variants of viruses in the circulation due to 
antigenic variations in HA genes and antigenic mismatching between viruses present in 
circulation and virus present in vaccine strains, are the major cause of current vaccine 
failures (Palese and Garcia-Sastre, 2002; Daly, Newton and Mumford, 2004). The 
conventional vaccines are found to induce specific antibodies to circulating strains of 
viruses, and elicit only humoral immunity, and are therefore not very effective. DNA 
vaccines have the potential to overcome these short-falls because they have the 
advantages of eliciting cell mediated responses like live vaccines and at the same time 
they are safer than the live vaccines. Another advantage for DNA vaccines is that 
multiple immunogenic genes can be engineered in the same vector. This will reduce the 
number of vaccinations required in horses. Similarly, it is believed that DNA vaccines 
can elicit immunity even in the presence of circulating antibodies and maternal antibodies 
will not hamper the effectiveness of DNA vaccines.  
5.2. Conclusions: 
 
Protective immunity was found in mice after intranasal vaccination with designed 
DNA vaccines pTOPOKY98#6 and pVAXKY98/11-9. The elevated IgG and IgA levels 
were recorded in sera of vaccinated groups of mice. Similarly, HA1 was found to be 
sufficient to elicit protective immunity against homologous challenge of equine-2 virus, 
A/Eq/ky/98 in mice.  
 
69
It was found that the intranasal route using liposome and metastim as adjuvants 
was very effective. While using the weight loss model, no significant differences were 
observed between two different vaccinated groups pTOPOKY98 and pVAXKY98 and no 
significant differences were observed between liposome and metastim treatment groups. 
IgG mean O.D. values were higher in the pVAX group and metastim treatment group in 
comparison to the pTOPO group and the liposome treatment group respectively while no 
significant difference was found in the case of IgA mean O. D. values in these groups and 
treatments. More importantly, dose levels as low as 0.01 µg DNA/gram body-weight 
were sufficient to elicit protective immunity against a sub-lethal challenge in mice. 
 
Therefore, DNA vaccines have a great potential to replace currently 
available vaccines for equine influenza virus. It is expected that these designed vaccines 
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Appendix – A 
 
The GLM Procedure for Weight Loss Model 
 
Class         Levels      Values                                                
 
group              7      group1 group2 group3 group4 group5 group6 group7      
 
Dependent Variable: day_3                                                  
 
Sum of                                    
 Source                     DF         Squares     Mean Square     F Value    Pr > F  
 
Model                       6      18.84537833      3.14089639        4.75    0.0024  
 
Error                        25      16.54342167      0.66173687                     
 
Corrected Total       31      35.38880000   
 
Dunnett's t Tests for day_3                            
 
This test controls the Type I experimentwise error for comparisons of all treatments against a control.                        
 
Alpha                               0.05                      
 Error Degrees of Freedom               25                      
 Error Mean Square                   0.661737 
 Critical Value of Dunnett's t            2.76322 
 
Comparisons significant at the 0.05 level are indicated by ***.          
 
Difference                                        
 group              Between      Simultaneous   95%                   
 Comparison             Means     Confidence   Limits                   
 
group5 - group1         2.2440       0.8224     3.6656  ***              
 group4 - group1         1.7800        0.3584     3.2016  ***              
 group3 - group1         1.5900        0.1684     3.0116  ***              
 group6 - group1         1.5613     -0.0802     3.2029  ***                  
 group2 - group1         1.6805     - 0.0827     3.2018  ***                  
 group7 - group1         0.5240      -0.8976    1.9456     
 
Note: SAS output for Weight loss model in mice on day 3 after Virus challenge. A Proc GLM procedure 
was used for analysis of F value and p value and determination of significance. A Dunnett’s t Test was used 
to compare each treatment with negative control group 1. 
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Appendix - B 
 
The GLM Procedure for IgG 
 
Class         Levels      Values                                                
 
group              7      group1 group2 group3 group4 group5 group6 group7      
 
Dependent Variable: day_42                                                 
 
Sum of                                    
 Source                     DF        Squares     Mean Square     F Value    Pr > F  
 
Model                       6       1.86237988      0.31039665       85.82     <.0001  
 
Error                        25       0.09042345      0.00361694                     
 
Corrected Total       31       1.95280333 
Dunnett's t Tests for day_42                            
 
This test controls the Type I experimentwise error for comparisons of all treatments against a control.                        
 
Alpha                               0.05                      
 Error Degrees of Freedom               25                      
 Error Mean Square                    0.003617                      
 Critical Value of Dunnett's t              2.76322                      
 
Comparisons significant at the 0.05 level are indicated by ***.          
 
Difference                                        
 group              Between      Simultaneous   95%                   
 Comparison             Means     Confidence   Limits                   
 
group4 - group1        0.65478      0.54968    0.75988  ***              
 group2 - group1        0.49880     0.38732    0.61028  ***              
 group6 - group1        0.49740      0.37604    0.61876  ***              
 group5 - group1        0.36850      0.26340    0.47360  ***              
 group3 - group1        0.30170      0.19660    0.40680  ***              
 group7 - group1      -0.01330             -0.11840    0.09180 
Note: SAS output for IgG titer on day 42, three weeks after booster vaccination. A Proc GLM procedure 
was used for analysis of F value and p value and determination of significance. A Dunnett’s t Test was used 
to compare each treatment with negative control group 1. 
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Appendix - C 
 
The GLM Procedure for IgA 
 
Class         Levels      Values                                                
 
group              7      group1 group2 group3 group4 group5 group6 group7      
 
Dependent Variable: day_42                                                 
 
Sum of                                    
Source                     DF        Squares     Mean Square     F Value    Pr > F  
Model                       6       0.59200313      0.09866719       50.69     <.0001  
Error                        25       0.04866660      0.00194666                     
 
Corrected Total       31       0.64066973 
Dunnett's t Tests for day_42                            
 
This test controls the Type I experimentwise error for comparisons of all treatments against a control.                        
 
Alpha                               0.05                      
 Error Degrees of Freedom               25                      
 Error Mean Square                    0.001947 
 Critical Value of Dunnett's          2.76322 
 
Comparisons significant at the 0.05 level are indicated by ***.          
 
Difference                                        
 group              Between      Simultaneous   95%                   
 Comparison             Means     Confidence   Limits                   
 
group6 - group1        0.33760     0.24857    0.42663  ***              
 group5 - group1        0.32040      0.24329    0.39751  ***              
 group4 - group1        0.18120      0.10409    0.25831  ***              
 group3 - group1        0.14870      0.07159    0.22581  ***              
 group2 - group1        0.12520     0.04342    0.20698  ***              
 group7 - group1      -0.06220    -0.13931    0.01491                                                                                        
Note: SAS output for IgA titer on day 42, three weeks after booster vaccination. A Proc GLM procedure 
was used for analysis of F value and p value and determination of significance. A Dunnett’s t Test was used 
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